Description eplerenone, an aldosterone receptor antagonist similar to spironolactone, has been shown to produce sustained increases in plasma renin and serum aldosterone, consistent with inhibition of the negative regulatory feedback of aldosterone on renin secretion. the resulting increased plasma renin activity and aldosterone circulating levels do not overcome the effects of eplerenone. eplerenone selectively binds to recombinant human mineralocorticoid receptors relative to its binding to recombinant human glucocorticoid, progesterone and androgen receptors.mechanism of action eplerenone binds to the mineralocorticoid receptor and thereby blocks the binding of aldosterone (component of the renin-angiotensin-aldosterone-system, or raas). aldosterone synthesis, which occurs primarily in the adrenal gland, is modulated by multiple factors, including angiotensin ii and non-raas mediators such as adrenocorticotropic hormone (acth) and potassium.